169 related articles for article (PubMed ID: 11052632)
1. A phase I study of prolonged ambulatory infusion carboplatin with oral etoposide showing activity in prostate cancer.
Olver IN; Stephenson J; Schulze D
Cancer Chemother Pharmacol; 2000; 46(4):338-41. PubMed ID: 11052632
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of prolonged ambulatory infusion carboplatin and oral etoposide for patients progressing through hormonal therapy for prostate cancer.
Olver I; Keefe D; Myers M
Intern Med J; 2005 Jul; 35(7):405-8. PubMed ID: 15958110
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
Smith DC; Chay CH; Dunn RL; Fardig J; Esper P; Olson K; Pienta KJ
Cancer; 2003 Jul; 98(2):269-76. PubMed ID: 12872344
[TBL] [Abstract][Full Text] [Related]
4. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
Chang AY; Boros L; Garrow GC; Asbury RF; Hui L
Semin Oncol; 1996 Jun; 23(3 Suppl 6):74-7. PubMed ID: 8677454
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.
Oh WK; Hagmann E; Manola J; George DJ; Gilligan TD; Jacobson JO; Smith MR; Kaufman DS; Kantoff PW
Clin Cancer Res; 2005 Jan; 11(1):284-9. PubMed ID: 15671557
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer.
Planting A; Kho S; van der Burg M; Goey H; Schellens J; van den Bent M; van der Gaast A; de Boer-Dennert M; Stoter G; Verweij J
Cancer Chemother Pharmacol; 1997; 40(4):347-52. PubMed ID: 9225954
[TBL] [Abstract][Full Text] [Related]
7. Duration: escalation study of oral etoposide with carboplatin in patients with varied solid tumors.
Thiery-Vuillemin A; Dobi E; Nguyen T; Royer B; Montange D; Maurina T; Kalbacher E; Bazan F; Villanueva C; Demarchi M; Chaigneau L; Ivanaj A; Pivot X
Anticancer Drugs; 2010 Nov; 21(10):958-62. PubMed ID: 20856105
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma.
Hainsworth JD; Stroup SL; Greco FA
Cancer; 1996 Jun; 77(12):2458-63. PubMed ID: 8640693
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel, carboplatin, and oral etoposide in the treatment of small cell lung cancer.
Greco FA; Hainsworth JD
Semin Oncol; 1996 Dec; 23(6 Suppl 16):7-10. PubMed ID: 9007113
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
Palackdharry CS
Semin Oncol; 1996 Jun; 23(3 Suppl 6):78-83. PubMed ID: 8677455
[TBL] [Abstract][Full Text] [Related]
12. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
14. Oral etoposide and oral prednisone for the treatment of castration resistant prostate cancer.
Zhu YP; Yao XD; Zhang SL; Dai B; Zhang HL; Shen YJ; Zhu Y; Shi GH; Lin GW; Ye DW
Kaohsiung J Med Sci; 2014 Feb; 30(2):82-5. PubMed ID: 24444537
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.
Meerpohl HG; du Bois A; Kühnle H; Lück HJ; Kreienberg R; Möbus V; Bauknecht T; Köchli O; Bochtler H; Diergarten K
Semin Oncol; 1995 Dec; 22(6 Suppl 15):7-12. PubMed ID: 8643973
[TBL] [Abstract][Full Text] [Related]
16. Combination chemotherapy using carboplatin (JM-8) and etoposide (JET therapy) for recurrent malignant gliomas: a phase II study.
Watanabe K; Kanaya H; Fujiyama Y; Kim P
Acta Neurochir (Wien); 2002 Dec; 144(12):1265-70; discussion 1270. PubMed ID: 12478337
[TBL] [Abstract][Full Text] [Related]
17. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
[TBL] [Abstract][Full Text] [Related]
18. Pilot study of ambulatory infusional delivery of a multidrug regimen: ifosfamide, carboplatin and etoposide (ICE).
Lokich J; Anderson N; Moore C; Bern M; Coco F; Dow E
J Infus Chemother; 1996; 6(1):39-42. PubMed ID: 8748006
[TBL] [Abstract][Full Text] [Related]
19. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
Marsland TA; Garfield DH; Khan MM; Look RM; Boehm KA; Asmar L
Lung Cancer; 2005 Jan; 47(1):111-20. PubMed ID: 15603861
[TBL] [Abstract][Full Text] [Related]
20. A phase I report of paclitaxel dose escalation combined with a fixed dose of carboplatin in the treatment of head and neck carcinoma.
Dunphy FR; Boyd JH; Kim HJ; Dunphy CH; Harrison BR; Dunleavy TL; Rodriguez JJ; McDonough EM; Minster JR; Hilton JG
Cancer; 1997 May; 79(10):2016-23. PubMed ID: 9149030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]